Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
JCR Pharmaceuticals Co Ltd
4552JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan. Address: 3-19 Kasuga-cho, Ashiya, Japan, 659-0021
Analytics
WallStreetin tavoitehinta
134 071.71 JPYP/E-suhde
–Osinkotuotto
3.26 %Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut 4552
Osinkoanalytiikka 4552
Osinkojen kasvu 5 vuoden aikana
196 %Jatkuva kasvu
2 vuottaMaksusuhde 5 vuoden keskiarvo
43 %Osinkohistoria 4552
Osakkeen arvostus 4552
Talousasiat 4552
Tuloksia | 2019 | Dynamiikka |